The SCN8A gene early infantile epileptic encephalopathy type 13 genetic test is a specialized diagnostic tool aimed at identifying mutations in the SCN8A gene, which have been linked to a severe form of epilepsy known as early infantile epileptic encephalopathy type 13 (EIEE13). This condition is characterized by frequent seizures that begin in the first months of life, often accompanied by developmental delays and other neurological issues. The SCN8A gene plays a crucial role in the functioning of brain cells, and mutations in this gene can disrupt the normal electrical activity in the brain, leading to epilepsy.

The test is available at DNA Labs UAE, a leading provider of genetic testing services in the United Arab Emirates. The cost of the test is 4400 AED, which reflects the specialized nature of the analysis and the sophisticated technology employed to accurately detect mutations in the SCN8A gene. By identifying these genetic mutations, the test can provide crucial information for the diagnosis and management of early infantile epileptic encephalopathy type 13, enabling healthcare providers to tailor treatment plans to the specific needs of their patients. This can include targeted therapies that may be more effective based on the patient’s genetic makeup, thereby improving outcomes and enhancing the quality of life for those affected by this challenging condition.